CanSino Biologics Balance Sheet Health

Financial Health criteria checks 4/6

CanSino Biologics has a total shareholder equity of CN¥5.1B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 41.2%. Its total assets and total liabilities are CN¥8.6B and CN¥3.5B respectively.

Key information

41.2%

Debt to equity ratio

CN¥2.10b

Debt

Interest coverage ration/a
CashCN¥4.01b
EquityCN¥5.11b
Total liabilitiesCN¥3.46b
Total assetsCN¥8.57b

Recent financial health updates

Recent updates

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07
Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

May 12
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Jan 09
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Sep 16
CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Aug 31
Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Aug 29
Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13
Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01
Is CanSino Biologics (HKG:6185) Using Too Much Debt?

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15
We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11
CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26
Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01
CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear

Sep 05
CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear

Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?

Jul 03
Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?

Financial Position Analysis

Short Term Liabilities: 6185's short term assets (CN¥5.0B) exceed its short term liabilities (CN¥2.1B).

Long Term Liabilities: 6185's short term assets (CN¥5.0B) exceed its long term liabilities (CN¥1.4B).


Debt to Equity History and Analysis

Debt Level: 6185 has more cash than its total debt.

Reducing Debt: 6185's debt to equity ratio has increased from 29.9% to 41.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6185 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6185 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.